Tang Gaoyan, Zhang Yuping, Meng Wenjuan, Zhong Shoubin, Feng Hui, Yu Guohua, Liu Shuzhen, Li Rui
Department of Oncology, Weifang People's Hospital (The First Affiliated Hospital of Shandong Second Medical University), Weifang, China.
Center for Precision Pathological Diagnosis, Weifang People's Hospital (The First Affiliated Hospital of Shandong Second Medical University), Weifang, China.
Front Oncol. 2025 Apr 28;15:1540868. doi: 10.3389/fonc.2025.1540868. eCollection 2025.
Retroperitoneal liposarcoma (RPLS) is a rare malignant mesenchymal tumor originating in the retroperitoneal space. It is characterized by a low incidence, poorly understood etiology and pathogenesis, and diverse imaging and pathological manifestations. The malignancy of RPLS varies significantly among cases. Currently, surgical resection remains the primary treatment for primary retroperitoneal liposarcoma; however, the disease is associated with a high and rapid recurrence rate, which severely impacts patient prognosis. This study presents a case of recurrent retroperitoneal liposarcoma treated with iodine-125 seed implantation following surgical intervention. Due to the large tumor size, high risk of postoperative recurrence, and the challenges of accurately targeting postoperative radiotherapy, surgical re-intervention was deemed unsuitable. Consequently, a comprehensive treatment plan involving iodine-125 seed implantation combined with anlotinib therapy was formulated. The patient achieved stable disease control over a 3-year follow-up period, demonstrating the potential efficacy of this combined therapeutic approach. This case highlights the antitumor potential of iodine-125 seed implantation combined with anlotinib in the management of retroperitoneal liposarcoma, particularly in cases where surgical options are limited.
腹膜后脂肪肉瘤（RPLS）是一种起源于腹膜后间隙的罕见恶性间叶组织肿瘤。其特点是发病率低、病因和发病机制尚不清楚，以及影像学和病理表现多样。RPLS的恶性程度在不同病例中差异很大。目前，手术切除仍然是原发性腹膜后脂肪肉瘤的主要治疗方法；然而，该疾病的复发率高且迅速，严重影响患者预后。本研究报告了1例复发性腹膜后脂肪肉瘤患者，在手术干预后接受碘-125粒子植入治疗。由于肿瘤体积大、术后复发风险高以及术后精确放疗定位的挑战，再次手术干预被认为不合适。因此，制定了一项包括碘-125粒子植入联合安罗替尼治疗的综合治疗方案。在3年的随访期内，患者病情得到稳定控制，证明了这种联合治疗方法的潜在疗效。该病例突出了碘-125粒子植入联合安罗替尼在腹膜后脂肪肉瘤治疗中的抗肿瘤潜力，特别是在手术选择有限的情况下。
